WaveMan
WaveMan · Company
CNXU · Conexeu Sciences Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CNXU Conexeu Sciences (CNXU) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0002066836
Quote by TradingView
Activist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $1.2K priced

What the filings say about CNXU

Insiders, 180 days
+$662.0K net bought
1 buyer
Activist stakes (13D), 180 days
1 filing
Largest: 5.4% of the class

Conexeu Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Conexeu Sciences Inc. insiders bought a net $662.0K of stock across 2 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Purcell Lynn Sebastian
Director
BUY
2026-10-19 SECtraded 2026-10-15
166,666
$500.0K
-1.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 18, 2026.
  • The trade is 5.3% of the 3,118,514 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Purcell Lynn Sebastian bought about $500.0K of CNXU on Oct 15, 2026, the largest insider purchase at the company on our record; 8 funds added in the latest 13F quarter.
Purcell Lynn Sebastian
Director
BUY
2026-06-23 SECtraded 2026-06-18
202,500
$162.0K
-72.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.4% of the 2,734,240 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Purcell Lynn Sebastian bought about $162.0K of CNXU on Jun 18, 2026, the largest insider purchase at the company on our record; 8 funds added in the latest 13F quarter.
2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$662.0K over 180 days
+$500.0K over 90 days · +$662.0K of it by a 10%+ holder
more than 89% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 88% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 75% of Medical Devices
The situation: each line is one rule over one dataset
Jeffrey Sharpe disclosed a 5%+ stake (5.4%) in the last six months.
What changed in the last 30 days
Oct 19Director Purcell Lynn Sebastian bought $500.0K (Oct 15)

Watch CNXU

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.5%12M
-78%-42%-7%+29%2026-052026-062026-072026-082026-092026-092026-10 2026-10-15 · Purcell Lynn Sebastian bought $500.0K2026-06-18 · Purcell Lynn Sebastian bought $162.0K2026-08-18 · Jeffrey Sharpe filed a 5%+ stake (5.4%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CNXU: institutional holders (13F)

13F holdings, latest reported quarter
UBS Group AG
12,264 sh
$133.9K
MORGAN STANLEY
5,871 sh
$64.1K
CITIGROUP INC
5,219 sh
$57.0K
HOLLENCREST CAPITAL MANAGEMENT
1,000 sh
$10.9K
ROYAL BANK OF CANADA
887 sh
$10.0K

Congress trades in CNXU

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Jeffrey Sharpe
Activist 13D · 2026-08-18
5.4%

CNXU planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $662.0K bought by insiders over 180 days, 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

CNXU Stock Sonar score 3/7 axes

Find similar shapesCompare

CNXU ranks highest on risk and compliance (76th percentile) and insider conviction (70th), and lowest on institutional and government (12th), among Medical Devices peers.

Insider conviction
70
Inputs
  • Net Form 4 buying (codes P and S), 180d$662K · 89 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
12
Inputs
  • Funds adding, latest quarter8 · 12 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
76
Inputs
  • Short interest, % of float+1.4% · 76 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CNXU filings, in plain words

Are Conexeu Sciences insiders buying or selling CNXU?

In the 180 days to 2026-10-28, Conexeu Sciences insiders were net buyers, a net $662.0K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Conexeu Sciences insiders were net buyers of CNXU, a net $662.0K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $662.0K, came from a holder of 10% or more rather than an officer or director. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 5.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies